Triple-negative breast cancer (TNBC) comprises 15–20% of all BRCA cases and is characterized by the absence of the estrogen receptor (ER) and progesterone receptor (PR) expressions, as well as a lack of human epidermal growth factor receptor 2 (HER2) overexpression or amplification [2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.